Aesica Appoints Bhavesh Kotecha to Newly Created Position of CSD
News Aug 29, 2013
Aesica has appointed Bhavesh Kotecha to the new position of Corporate Services Director (CSD). Reporting directly to the CEO of Aesica, Dr. Robert Hardy, Bhavesh will take functional responsibility for delivering operational efficiency and high standards across IT, health and safety, internal audit and M&A processes.
One of the CSD’s key responsibilities is the use of IT for further efficiency in the running of M&A processes. The Corporate Services Director with the new team structure will serve as an important asset to the Aesica acquisition strategy, with business integration teams being guided by Bhavesh.
The corporate service discipline is a critically important function to meet the transitional challenges that stem from the acquisition process, thereby ensuring the full integration of all functions including finance, HR, sales and marketing, quality control, health and safety regimes, structures and regulatory compliance.
Bhavesh’s combined functions input into the management of strategy, cost in line with pre-set budgets, new technologies and ERP systems.
Aesica has established an integrated team structure to assist the CSD with his multiple responsibilities and the effective implementation of best practice programmes and quality control across his functional competencies within the company.
He is supported in his role by three IT country managers, a global health and safety manager and specialist technical architect.
Commenting on the Corporate Services Director’s role, Dr. Robert Hardy, Aesica CEO said: “The CSD position and responsibilities are crucial to the Aesica strategy and will be central to maximizing efficiency and operational performance, ensuring compliance with the highest standards of health and safety, whilst achieving the optimum integration of personnel, corporate infrastructure, technology and processes as we continue to make strategic acquisitions”.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE